Pipeline to success for blood clotting research

Prof Mark Sleeman (left) & A/Prof Justin
Hamilton (right)

Australian Centre for Blood Diseases (ACBD) researchers are pushing their discovery of a promising anti-thrombotic agent towards clinical trial as part of a Monash University collaboration with a US biotechnology company. Here’s how the deal was brokered.

by Anne Crawford

In 2014 the ACBD’s Associate Professor Justin Hamilton approached Professor Mark Sleeman at the Monash Biomedicine Discovery Institute (BDI) with a proposal. Professor Sleeman, amongst other roles at Monash Clayton, is the Director of the Monash Antibody Technologies Facility (MATF).